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Abstract
Background: The costs and benefits of controlling nosocomial spread of antibiotic-resistant bacteria are unknown.
Methods: We developed a mathematical algorithm to determine cost-effectiveness of infection control programs and
explored the dynamical interactions between different epidemiological variables and cost-effectiveness. The algorithm
includes occurrence of nosocomial infections, attributable mortality, costs and efficacy of infection control and how
antibiotic-resistant bacteria affect total number of infections: do infections with antibiotic-resistant bacteria replace
infections caused by susceptible bacteria (replacement scenario) or occur in addition to them (addition scenario).
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was used for illustration using observational data on S. aureus
bacteremia (SAB) in our hospital (n=189 between 2001–2004, all being methicillin-susceptible S. aureus [MSSA]).
Results: In the replacement scenario, the costs per life year gained range from J 45,912 to J 6590 for attributable mortality
rates ranging from 10% to 50%. Using J 20,000 per life year gained as a threshold, completely preventing MRSA would be
cost-effective in the replacement scenario if attributable mortality of MRSA is $21%. In the addition scenario, infection
control would be cost saving along the entire range of estimates for attributable mortality.
Conclusions: Cost-effectiveness of controlling antibiotic-resistant bacteria is highly sensitive to the interaction between
infections caused by resistant and susceptible bacteria (addition or replacement) and attributable mortality. In our setting,
controlling MRSA would be cost saving for the addition scenario but would not be cost-effective in the replacement
scenario if attributable mortality would be ,21%.
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Introduction
Nosocomial infections caused by antibiotic-resistant bacteria,
such as methicillin-resistant Staphylococcus aureus (MRSA), pose a
global health care problem, resulting in direct costs associated with
increased health care consumption and indirect costs due to
morbidity and loss of life years [1–4]. There is considerable
geographic variation in incidence of such infections. Reported
MRSA rates among Staphylococcus aureus bloodstream infections are
still ,1% in countries with nationwide infection control policies
for MRSA, such as in Scandinavian countries and the Netherlands
[5], and have been as high as over 50% in countries without such
infection control programs (e.g. U.S.A.) [6,7] or where such
measures have been abandoned (e.g. United Kingdom) [8]. Yet,
such infection control strategies may affect quality of patient care
[9] and their effectiveness has not been unequivocally demon-
strated in settings with existing high endemic levels [10].
Costs and benefits of an infection control program are best
expressed in universal outcome measures, such as costs per (quality
adjusted) life year gained, but to the best of our knowledge, no
estimates of life years gained have been reported. In the present
study we developed a mathematical algorithm to determine cost-
effectiveness of containing infections with antibiotic-resistant
nosocomial pathogen. To illustrate its use and explore the
importance of several parameters we have applied the algorithm
to the MRSA epidemiology in our hospital, which had no case of
MRSA bacteremia between 1991 and 2004. The relevant
variables in this algorithm include the total number of S. aureus
bacteremias (SAB, which includes both MRSA and methicillin-
susceptible S. aureus (MSSA)), the attributable mortality due to
infection with a resistant pathogen (in this case MRSA), the costs
of infection control, the number of infections prevented (i.e.,
efficacy) and how antibiotic-resistant bacteria affect the total
number of SAB. Using available data from our hospital, and
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the effect of the epidemiological variables on the costs per life year
gained of our control policy.
Of note, a modeling approach always represents a huge
simplification of real life and is here used to demonstrate
differences across scenarios, rather than to precisely quantify
cost-effectiveness of infection control interventions. Hence, our
paper is not intended as an economic evaluation of our hospital
infection control policies, but merely as an exploration of the
dynamic interactions between important epidemiological param-
eters and cost-effectiveness of infection control policies.
Methods
Model design and parameters
A mathematical algorithm was developed (see Appendix S1 for
details), that included occurrence of nosocomial SAB, costs and
efficacy of infection control, attributable mortality, and the
interaction between MRSA and MSSA infection rates. We had
accurate estimates of the costs of the MRSA control policy in our
hospital [11], its efficacy during this period (being 100%),
incidence data of nosocomial SAB, and the characteristics of
patients developing nosocomial SAB. There is less certainty,
though, about the other variables in the algorithm: the attributable
mortality due to MRSA infection and how MRSA affect total
number of SAB. Estimates of attributable mortality of MRSA
bacteremia, as compared to MSSA, have ranged from 0% to 50%
[1–3,12–15]. The interaction between MRSA and MSSA
infection rates is also largely unknown. Some data suggest that
MRSA infections replace MSSA infections with no effects on the
total burden of Staphylococcus aureus infections (a scenario further
referred to as ‘‘replacement’’) [16,17]. Other reports suggest that
rising incidences of nosocomial MRSA infections add to the
incidence of MSSA infections, and that reductions in MRSA
infections (through intervention programs) leave MSSA infection
rates unaffected [8,18,19]. In this scenario (further referred to as
‘‘addition’’) emergence of MRSA would increase the total burden
of Staphylococcus aureus infections. Cost-effectiveness was determined
for different ranges of the two possible scenarios in which MRSA
either results in addition to or replaces cases of nosocomial MSSA
bacteremia and when both scenarios simultaneously occur. We
assumed that the proportion of MRSA bacteremia among SAB
with a less effective infection control strategy, would increase from
1% (as currently in the Netherlands [5]) up to 50% (as witnessed in
countries without a control policy [6,7]). The MRSA control
strategy is predominantly based on distancing carriers from non-
carriers to prevent exogenous transmission, and was, therefore,
assumed not to change MSSA bacteremia rates. Naturally,
eradication therapy for MRSA carriage could also reduce MSSA
infection rates [20], but this was only applied after hospital
discharge.
Setting
The University Medical Center in Utrecht, The Netherlands, is
a public teaching hospital with 1042 beds. Our MRSA policy is
based on the Dutch guideline [21] and includes isolation of all
patients colonized with MRSA and pre-emptive isolation of all
patients with high risks for colonization. In the latter, isolation
measures are discontinued when inventory cultures are negative. If
MRSA is unexpectedly found in a clinical culture, all contacts
(both patients and health care workers) are screened for MRSA
colonization. In case of an outbreak a ward may be temporarily
closed to new patients to prevent further spread. Eradication
therapy for MRSA carriage is only considered after hospital
discharge when patients are recovered with absence of wounds,
catheters etc. Our prevention strategy was 100% effective in
preventing MRSA bacteremia; because numbers of other MRSA
infections were negligible, these were not taken into account.
Data collection
All patients in our hospital with nosocomial SAB (defined as a
blood culture with S. aureus obtained more than 48 hours after
hospital admission) between 1 May 2001 and 30 April 2004 were
identified. Demographic and clinical information was, retrospec-
tively, determined from medical charts. The presence of
underlying chronic diseases such as chronic obstructive pulmonary
disease, diabetes mellitus, chronic renal insufficiency, cancer,
chronic cardiac disease and congenital anomalies was recorded.
For simplicity, we assumed a dichotomous comorbidity measure in
our analyses. Univariate logistic regression analysis was used to
determine whether age, gender and comorbidities were associated
with survival. Ethical approval was not required for this
retrospective case analysis.
Analyses
Using actual data of SAB incidence and costs of MRSA control
in our hospital, we calculated the costs per life year gained with
our MRSA policy. The total number of SAB equals the sum of
SAB caused by MSSA and MRSA. The difference between
observed mortality of SAB in our hospital and the estimated
mortality should a proportion of SAB episodes be caused by
MRSA, because of a less effective or no MRSA policy, represents
the crude number of lives gained with our infection control policy.
For those patients that survived SAB in our hospital, average
remaining life expectancy was determined using life tables from
Statistics Netherlands, which were adjusted for age. We assumed
that the presence of comorbidities decreases ones life expectancy
with 30% [22,23]. Effects (life years gained) were discounted at
1.5%, as recommended in the Netherlands [24]. The cost per life
year gained were subsequently calculated as the incremental costs
for infection prevention and additional length of hospital stay of
survivors, divided by the life years gained, for a period of one year
of executing Dutch MRSA policy.
Costs
The cost analysis was performed from a hospital perspective.
Costs include costs of infection prevention and incremental costs
due to increased length of stay of survivors. The annual costs of
MRSA infection control in our hospital were calculated in 2000
[11], being J 277,400, which included costs for microbiological
cultures, disposable infection prevention material, cleaning and
decontamination, loss of hospitalization days and surgical
procedures during outbreaks, temporary suspension of health care
workers from work and treatment of MRSA carriers. The costs
related to MRSA control in our hospital for the year 2000 have
been adapted to 2004 using the consumer price index as collected
by Statistics Netherlands and were for simplicity fixed at J
308,533 per year. The costs for additional length of hospital stay
attributable to SAB were calculated as the difference between the
costs for hospital stay after SAB had been diagnosed with the
infection control policy and the costs for hospital stay should SAB
have been diagnosed without the infection control policy. The
latter estimation was based on expected survival and death rates of
patients without infection control and the costs of hospital stay for
survivors and non-survivors as observed in the patients in our
hospital.
Costs of hospital stay were J 1684 and J 337 for an ICU and
non-ICU day, respectively, which are the general cost prices
Costs of Infection Control
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2004 [24]. Costs were expressed in Euros and not discounted, as
all costs (infection prevention policy, hospitalization) are made in
one year.
Sensitivity analyses
We explored which uncertain variables were of most influence
on the cost-effectiveness in both scenarios (replacement or
addition). We have used a distribution of attributable mortality
of MRSA bacteremia as compared to MSSA bacteremia, from 0%
to 50% [1–3,12–15]. We varied the proportion of MRSA
bacteremia among SAB with a less effective or no infection
control strategy from 10% to 50%. Also we explored the outcome
with a less effective MRSA control policy, reducing MRSA
prevalence from 50% to 45%, up to 5%. Threshold analyses were
performed to determine break-even values for costs per life year
gained, i.e., when all costs of infection control plus all the costs
related to additional length of stay of surviving patients were
compensated by the savings due to less infections. For this
threshold analyses, the Dutch informal threshold of J 20,000 per
(quality adjusted) life year gained was used.
Results
Baseline characteristics
During the 3-year period, there were 189 patients with a
nosocomial SAB, all MSSA. 115 (61%) were male and ages of the
patients ranged from 0 months to 95 years (mean 39 years) with 48
(25%) infants. 117 (62%) patients had underlying comorbidity of
whom 75 (64%), 33 (28%) and 9 (8%) had one, two and three or
more chronic conditions, respectively. In 76 (40%) patients MSSA
bacteremia resulted from documented infected intravascular
devices. The all-cause in-hospital mortality of the patients was
16% (n=30). Differences between surviving and succumbing
patients are presented in Table 1. In logistic regression analysis,
age was associated with in-hospital mortality (odds ratio 1.03, 95%
confidence interval 1.01–1.05, p=0.002), the presence of gender
and comorbidities appeared non-significant.
Cost-effectiveness in the replacement and addition
scenario
In the replacement scenario, when the total burden of SAB
remains the same over time, while the prevalence of MRSA SAB
increases, there will always be incremental costs due to infection
control (Figure 1, Table 2). When MRSA would have no
attributable mortality there are no life years gained in the
replacement scenario and costs per life year gained would be
infinite. Considering the Dutch threshold value for cost-effective-
ness of J 20,000 per life year gained a MRSA infection control
strategy would be cost-effective when attributable mortality of
MRSA is $21% in the replacement scenario. In contrast, in the
addition scenario, the MRSA infection control policy reduces the
total absolute numbers of SAB and will always be cost-saving,
irrespective of attributable mortality (Figure 1, Table 2). Savings
increase with lower attributable mortality rates, as an increasing
number of SAB survivors generate higher additional health care
costs, compared to the non-survivors.
When the proportion of MRSA bacteremia among SAB
without an infection control strategy would be lower than 50%,
life years gained are less and costs per life year gained will be
higher for both scenarios (data not shown). Threshold analyses for
costs of infection control policies to be cost-effective are presented
in Table 2.
Effectiveness of infection control strategies
In Figure 2 we have depicted costs per life year gained as a
function of the effectiveness of an infection control policy and
attributable mortality. An infection control policy in the
replacement scenario will only be cost-effective, assuming the
Dutch threshold value for cost-effectiveness of J 20,000 per life
year gained, at higher attributable mortality rates and depends on
the effectiveness of the infection control strategy (Figure 2a). For
example, when the infection control strategy reduces MRSA
prevalence from 50% to 30% this will only be cost-effective if
attributable mortality is above 45%. If MRSA infections would be
additional to MSSA infections infection control strategies would
already be cost-neutral (i.e. paid back by additional savings) when
the MRSA prevalence is reduced from 50% to 40% with
attributable mortality of 0% and will be cost-saving with increasing
effectiveness of the MRSA control policy, for all levels of
attributable mortality (Figure 2b).
Mixing replacement and addition scenarios
Most probably both scenarios occur, and the ultimate effect of
an infection control policy will be a combination of absolute
reduction and replacement of infections. In Figure 3 we have
depicted the costs per life year gained as a function of this
interaction (horizontal axis) and the rate of attributable mortality
of MRSA as compared to MSSA (vertical axis).
With 100% replacement (no additional cases of SAB), costs per
life year gained will be over J 20,000 if attributable mortality is
less than 20%. Yet, if attributable mortality is 0%, there should be
at least an increase in SAB incidence of 7% to keep costs per life
year gained less than J 20,000. And, still without attributable
mortality, infection control would become cost-saving if the
increase in total SAB is more than 20%.
Discussion
We have developed an algorithm to determine the cost-
effectiveness of controlling nosocomial infections with antibiotic-
resistant bacteria, taking important epidemiological variables into
account. We conclude that, apart from obvious variables such as
Table 1. Baseline characteristics of patients with S. aureus
bacteremias (SAB) by outcome of hospital stay.
Outcome of patients with SAB
Survived N=159
Age, years (SD) 34 (31)
Life expectancy, undiscounted, adjusted for
comorbidity
38
Length of hospital stay ICU after SAB (SD) 14 (38)
Length of hospital stay general ward after SAB (SD) 24 (29)
Incremental costs of hospital stay after SAB (J)3 2 , 2 2 5
Death N=30
Age, years (SD) 61 (23)
Life expectancy, undiscounted, adjusted for
comorbidity
15
Length of hospital stay ICU after SAB (SD) 5 (12)
Length of hospital stay general ward after SAB (SD) 3 (5)
Incremental costs of hospital stay after SAB (J)9 3 1 9
Values are expressed as means.
doi:10.1371/journal.pone.0011562.t001
Costs of Infection Control
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attributable mortality (AM) of MRSA bacteremia, as compared to MSSA, ranging from 0% to 50%.
doi:10.1371/journal.pone.0011562.g001
Table 2. Costs, effects and break-even values for different attributable mortality rates in the replacement and addition scenario.
Attributable mortality
0% 10% 20% 30% 40% 50%
Life years gained, discounted
Replacement 0 7.0 15.7 26.8 41.7 62.3
Addition 227.9 252.3 282.6 320.9 371.3 440.3
Total incremental costs (J)
Replacement 308,533 321,384 335,305 352,822 377,885 410,557
Addition 21,092,781 21,056,128 21,011,708 2955,961 2884,808 2789,898
Cost per life year gained per year MRSA policy (J)
Replacement NA
b 45,912 21,357 13,165 9062 6590
Addition 24795 24186 23580 22979 22383 21794
Break-even values costs infection control policy per year (J)
a
Replacement NA
b 127,783 287,257 491,900 764,120 1,144,144
Addition 5,959,726 6,411,444 6,971,136 7,682,879 8,618,626 9,904,560
aAssuming the Dutch threshold value for cost-effectiveness of J 20,000 per life-year gained.
bNA, not applicable.
doi:10.1371/journal.pone.0011562.t002
Costs of Infection Control
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infection incidence rates caused by resistant and (more) susceptible
bacteria and the attributable mortality due to infections with
resistant bacteria have the largest impact on cost-effectiveness. The
latter two variables, though, have not been accurately quantified
for most pathogens, which seriously hampers evidence-based
decision making for many settings. Based upon recent studies the
attributable mortality due to MRSA infections probably is lower
than previously assumed [15,25], and our findings in the lower
range of attributable mortality should, therefore, be considered as
most realistic. Using the Dutch MRSA control policy as an
example we conclude that there is strong evidence that this policy
(being almost 100% effective) is cost-effective, and can even be
cost-saving from the hospital perspective, under the assumption
that MRSA infections would add to the total burden of nosocomial
S. aureus infections, and not replace current MSSA infections.
Figure 2. Costs per life year gained as a function of effectiveness of infection control policies and attributable mortality (AM). A) In
the replacement scenario. The 20,000 euro line on the vertical axis reflects the Dutch threshold value for cost-effectiveness. B) In the addition
scenario.
doi:10.1371/journal.pone.0011562.g002
Costs of Infection Control
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the cost of hospital care.
Cost-effectiveness analysis of controlling the spread of antibiot-
ic-resistant bacteria in high endemic settings has been attempted in
only few studies. In a French case-control study in an ICU with a
4% admission prevalence of MRSA, an infection control program
would be cost-saving compared to the mean costs attributable to
MRSA infections as long as the MRSA infection rate was reduced
by at least 14% [26]. And in another study in Germany, a MRSA
screening program, including pre-emptive contact isolation, was
cost-saving if at least 48% of the predicted hospital-acquired
MRSA infections would be prevented [27]. The MRSA
prevalence in this study was 20.6% in the screened high risk
group. Cost-savings achieved by screening and surveillance
programs in endemic settings [28–31] and during MRSA
outbreaks [32,33] have been reported. However, there has not
been a past cost analysis that took the possible scenarios of
replacement or addition into account, nor has the cost-effective-
ness of a MRSA control policy ever been expressed in costs per life
year gained.
As shown in this study, our MRSA control strategy would be
cost-effective and even cost-saving if MRSA infections would add
to the total number of S. aureus infections. However, when using
the same parameters for attributable mortality, costs of infection
prevention and MRSA prevalence, the same strategy might not be
considered cost-effective when MRSA infections would replace
nosocomial MSSA infections. Obviously, both scenarios will
coexist, excluding the possibility of a ‘‘100% additional’’ or
‘‘100% replacement’’ scenario. Up till now, only few studies
provide some quantification of this important parameter. In a
recent longitudinal study from the UK overall rates of SAB rose
between 1997 and 2004 which was due to an increase in MRSA
bacteremia added to a stable MSSA bacteremia rate [8], whereas
older studies provided evidence for replacement [16,17]. Impor-
tantly, in all studies only MRSA and MSSA infections were
considered. Yet, hospitalized patients are prone to colonization
and infection with many bacteria. And although preventing spread
of MRSA may reduce the incidence of MRSA infection, these
patients are still prone to infection with, for instance, Gram-
negative bacteria. Only considering MSSA and MRSA might
suggest a reduction in the total number of S. aureus infections
(supporting the scenario of addition), but might not be associated
with a reduction in the total number of nosocomial infections,
which would suggest replacement of MRSA by other antibiotic-
resistant bacteria. One might argue that the nosocomial infection
syndromes caused by S. aureus (mainly skin and soft tissue
infections, post-surgical wound infections and catheter-related
infections) do not overlap to a great extent with those caused by
Gram-negative bacteria, and that replacement might be more
relevant when reducing infections caused by certain multi-resistant
Gram-negative pathogens. Yet, to the best of our knowledge, there
are no studies available that have taken all different pathogens into
account when determining the cost-effectiveness of infection
control programs. With such data, the numbers of MSSA
infections as used in our algorithm should simply be replaced by
numbers of non-MRSA infections.
Naturally, threshold levels for costs per life year gained for
preventive measures are determined by political and societal
circumstances and will, therefore, differ per country. With the
current accepted costs per life year gained in the Netherlands of J
20,000 [34,35] our findings suggest that the Dutch infection
control policy is cost-effective or even cost-saving along the entire
range of estimates for attributable mortality rates for the addition
scenario. With the replacement scenario, though, there will always
be incremental costs due to infection control, which would be cost-
effective (according to Dutch standards) when attributable
mortality of MRSA is at least 21%. In our analyses we have used
Dutch standards for discounting life years gained, using annual
rates of 1.5%. With higher discount rates (3%), which are common
in the U.S.A. and the UK, the number of life years gained will be
lower resulting in higher costs per life year gained.
Our study has several limitations. First, our example of MRSA
control is based on data from a single tertiary care hospital in the
Netherlands, and may, therefore, not be fully generalizable to
hospitals with different care levels or to settings in other countries.
The costs associated with the MRSA policy have been calculated
for our hospital and were estimated to be J 308,533 per year
between 1991 and 2000 [11]. More recently the costs in another
large Dutch teaching hospital have been estimated at J 215,559
per year between 2001 and 2006 [36]. For simplicity, we have
used a fixed cost price, though when control measures would be
instituted in high endemic settings initial costs may well be higher.
Second, for several reasons we based our analysis on bacteremia
cases only, as they unequivocally represent infections and have
been used for determination of attributable mortality rates. If other
nosocomial infections would have been taken into account (e.g.
surgical or pulmonary) the results of our study might have been
different, depending on the life expectancy and survival rates of
patients with these infections. Third, accurately estimating
incremental length of hospital stay attributable to SAB is
hampered by omitted variable bias and simultaneity bias [37],
and our estimates, therefore might be relatively high. However as
we used incremental costs for additional length of hospital stay,
this did not influence our conclusions.
In conclusion, our study illustrates how cost-effectiveness of
controlling nosocomial infections with antibiotic-resistant bacteria
can be determined using a mathematical algorithm. Our
Figure 3. Mixing replacement and addition scenarios. Costs per
life year gained as a function of the absolute increase in MRSA
bacteremia incidence (horizontal axis) and the rate of attributable
mortality of MRSA as compared to methicillin-sensitive Staphylococcus
aureus (MSSA) (vertical axis) for the scenario that 50% of all S. aureus
bacteremias cases are caused by MRSA.
doi:10.1371/journal.pone.0011562.g003
Costs of Infection Control
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determine cost-effectiveness in other settings.
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